Ivermectin is proven to prevent and treat covid effectively in meta analyses of multinational implementations. Top doctors from FLCCC believe it can end the pandemic, but no governmental health agency has created a study or informed the public. In fact, they seem dead set against it, and the two studies on the horizon are beset by conflicts of interest. Why is this?
Could it be that would eliminate the Emergency Use Authorization and stop the payoff for vaccines? Because it is is off patent and pennies per dose, thus eliminating any profit scheme? The debate rages on, but the facts are clear, Ivermectin stops covid, both as a prophylactic (yes, a condom….) and as a treatment. Here is the latest on the science, with a touch of insight into the swindle. For more on that, read our text blog.
Best ivermectin meta analysis
Ivermectin for Prevention and Treatment of COVID-19 Infection
A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Earlier, at least 20 to 25 HCWs were getting infected with the virus daily.
After the workers started taking ivermectin, the number of infection has come down to one or two per day
Critique
The safety of the drug has been established by its large-scale use in the last four decades for
various indications such as onchocerciasis, scabies, head lice, and other parasitic infestations
In this 87th in a series of live discussions with Bret Weinstein and Heather Heying (both PhDs in Biology), we discuss the state of the world through an ...evolutionary lens.
In this episode, we discuss why SARS-CoV2 must be driven to extinction, why the currently available vaccines are unlikely to be able to do so, and why we therefore need additional tools in our toolkit. We address and rebut the recent Quillette article, which contained copious journalistic and scientific errors, and excluded evidence relevant to the questions under discussion. A written response will be published soon as well. Finally, we share an excerpt from A Hunter-Gatherer’s Guide to the 21st Century, chapter 4 (Medicine).
Get your Goliath shirts right here: store.darkhorsepodcast.org
Become a member of the DarkHorse LiveStreams, and get access to an additional Q&A livestream every month. Join at Heather's Patreon.
Like this content? Subscribe to the channel, like this video, follow us on twitter (@BretWeinstein, @HeatherEHeying), and consider helping us out by contributing to either of our Patreons or Bret’s Paypal.
Looking for clips from #DarkHorseLivestreams? Here are some, updated frequently: @DarkHorse Podcast Clips
Theme Music: Thank you to Martin Molin of Wintergatan for providing us the rights to use their excellent music.
Timestamps:
00:00 Welcome and announcements
03:39 Quillette article introduction
05:11 It's not the box, it's the business model
08:36 Traditional vaccines and pills
13:01 Design failures of COVID vaccines
16:01 Perverse incentives of vaccine manufacturers
19:14 Prophylaxis Vs treatments and corporate responsibility
28:50 Bad Pharma and money in big science
36:10 Scientific errors in Quillette article
39:14 Prophylaxis Vs treatments Quillette confusion
41:40 Argentinean prophylaxis study
01:00:01 Other evidence for prophylaxis in Tess Lawrie's paper and in India and Africa
01:09:45 Randomised controlled trials and mortal rigor
01:12:50 Extended Use Authorization
01:13:55 Pro vaccine and anti im
01:17:02 Safety record of im
01:28:40 Vaccine deaths being reported as COVID deaths https://www.researchgate.net/publication/352837543_Analysis_of_COVID-19_vaccine_death_reports_from_the_Vaccine_Adverse_Events_Reporting_System_VAERS_Database_Interim_Results_and_Analysis
01:31:41 Bells palsy and outdated "fact checks"
01:40:40 Chapter 4 excerpt
01:48:08 Wrap up[+] Show More
active
Ivermectin, Mexico, Peru, India
Ivermectin and the odds of hospitalization due to COVID-19: evidence ...
Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City
Increase in COVID-19 ...cases and with critical levels of hospital saturation during December 2020
Mexico City Government decided to expand population-based health
Interventions
Implementation of a prehospital home-care program
Combining early detection with antigen tests
230 kiosks
Phone-based follow up for positive patients
Since 28 December, 2020, medical ivermectin kits have been provided to positive mild to moderate symptomatic patients
Dyspnea, chest pain or cyanosis, referred to a hospital
Ivermectin, four 6mg tablets, two pills for two days
After one month, 83,000 medical kits delivered
Detailed data was collected on the evolution of patient illnesses
Quasi-experimental evaluation of the effects of the medical kits on
hospitalization
Kit receivers and non-kit receivers
Matched observations, adjusting by age, sex, COVID severity, and comorbidities
Controls, N = 156,468 patients with COVID-19 infection before implementing the ivermectin program
Experimental group, n = 77,381 after the implementation
Outcome variable: whether or not the person was hospitalized
Results
Negative and significant effect of the ivermectin-based medical kit on
the probability of hospitalization
Effect ranges from 50% to 76%
Difference in hospitalization odds between treated and untreated patients, statistically significant in all cases
As expected, the effect of the medical kits is higher and stronger among males, in older patients, and in cases without severe symptoms
Discussion and limitations
we found that the medical kit given en masse to patients who’d tested positive in Mexico City had a negative, significant, and robust effect on their odds of being hospitalized.
Independently of the medical telephone follow, level of hospital occupancy, specific period of time
Similar trend, Perú (Chamie-Quintero Et Al, 2021).
Principal mechanisms, reduction of viral load, in the patients that take ivermectin in early stages of the disease
Uttar Pradesh government, first to have introduced a large-scale “prophylactic and therapeutic” use of Ivermectin
Helped the state to maintain a lower fatality and positivity rate as compared to other states
Health Department introduced Ivermectin as prophylaxis for close contacts of Covid patients, August 6, 2020
Agra, Dr Anshul Pareek and State Surveillance Officer Vikssendu Agrawal
Administered Ivermectin to all RRT team members in Agra
None of them developed Covid-19
Despite being in daily contact
Despite being the state with the largest population base and a high population density, we have maintained a relatively low positivity rate and cases per million of population
Lower positivity and fatality rates may be attributed to the large-scale use of Ivermectin use UP[+] Show More
active
Ivermectin discussion with Dr Tess Lawrie
Therapeutics and COVID-19: living guideline (WHO) ...
CATalyst | Ivermectin: Indian Bar Association Serve Legal Notice on WHO's Chief Scientist
Join the Conversation! | https://trialsitenews.com/ In the first ...
Join the Conversation! | https://trialsitenews.com/
In the first edition of CATalyst, Shabnam Palesa Mohamed engages Advocate Dipali Ohja (IBA), Dr Pierre Kory (FLCCC), and Dr Tess Lawrie (EBMC) about the Indian ...Bar Association's decision to issue legal notice on WHO chief scientist, Dr Soumya Swaminathan. The 51 page notice, served 25th of May, claims as its legal basis alleged WHO's 'disinformation and censorship' on the Ivermectin issue.
#CATalyst #TrialSiteNews #TrialSiteNewsAfrica #TSNA[+] Show More
active
Beyond The Roundup | First EU Nation To Approve Ivermectin For Covid-19
Slovakia Becomes the First EU Nation to Formally Approve Ivermectin ...
Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients:
The Slovakia Republic’s Minister of Health has formerly registered Ivermectin as an approved ...prophylaxis and treatment for SARS-CoV-2, the virus behind COVID-19. In breaking news, the authorization occurred as doctors received the news that they could proceed with formally authorized prescriptions both in hospitals and outpatient. On January 26, Health Minister Marek Krajci granted a permit for the unregistered drug as the drug has already been in use on a compassionate basis over the past half year. TrialSite interviewed Ondrej Halgas, a researcher from University of Toronto and originally from Slovakia. Halgas has been actively involved with a network organizing and lobbying for the drug’s approval during the pandemic. https://trialsitenews.com/slovakia-becomes-the-first-eu-nation-to-formally-approve-ivermectin-for-both-prophylaxis-and-treatment-for-covid-19-patients/[+] Show More
100% protection against moderate and severe disease
All hospitalizations and deaths ...in placebo group
90.4% efficacy overall
91% efficacy in high-risk populations
(over 65 or comorbidities)
N = 29,960, 119 sites, U.S. and Mexico
File for regulatory authorizations in the third quarter
100 million doses per month, then 150 million per month by end of 2021
UK, with GlaxoSmithKline, 60 million doses, Barnard Castle
Results: Consistent, high efficacy among circulating variants
77 infections
Placebo group, 63
Ten moderate cases and four severe
Vaccine group, 14 in the vaccine group
All cases observed in the vaccine group were mild
January 25 through April 30, 2021
Alpha (B.1.1.7) variant, became the predominant strain in the U.S
100% efficacy against variants not considered VoC/Vo
Favorable safety profile
Generally well-tolerated
Serious and severe adverse events few, balanced between vaccine and placebo groups
Injection site pain and tenderness, generally mild to moderate, lasting less than 3 days
Fatigue, headache and muscle pain, lasting less than 2 days
The placebo-controlled portion of PREVENT-19 continues in
Adolescents, 12 to 18 years of age
Completed enrolment, n = 2,248
Operation Warp Speed, awarded Novavax $1.6 billion contract for 100 million future doses
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Sheba Medical Center, and Tel Aviv University
Ivermectin is an FDA-approved broad spectrum anti-parasitic agent
Initially approved in humans in 1987
Nobel prize of Medicine in 2015
With its high safety profile, ivermectin is a potential treatment against COVID-19 in its different stages.
To assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection
Double blinded randomized control trial
Patients receiving ivermectin 0·2 mg/kg for 3 days vs placebo
Non-hospitalized COVID-19 patients
RT-PCR, recruitment and then every two days
Primary endpoint was reduction of viral-load on the 6th day
As reflected by Ct level more than 30 (non-infectious level)
Primary outcome was supported by determination of viral culture viability
Results
N = 89
Ivermectin group, 47
Placebo group, 42
Females, 21·6%
Asymptomatic at recruitment, 16.8%
Symptomatic, 83%
On day 6
Ivermectin group
34 out of 47 (72%) reached the endpoint, (non-infectious level)
Placebo group
21 out of 42 (50%) reached the endpoint, (non-infectious level)
Odds of a negative test at day 6 was 2.62 time higher in the ivermectin group
Also
Ivermectin group, cultures at days 2 to 6 were positive in 3/23 (13·0%)
Placebo group, cultures at days 2 to 6 were positive in 14/29 (48·2%)
(p=0·008)
3 hospitalisations, 3 in the placebo group
Diarrhoea, 2 and 1
No other adverse effects were reported
Conclusions
There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.[+] Show More
active
Ivermectin advised for India
WHO, India VOC, global concern https://www.who.int ...
British Ivermectin Recommendation Development (BiRD) panel
Re-purposed existing drugs
Ivermectin, a safe medicine which has been used for nearly 40 years to treat parasitic infections
3.7 billion people have been treated with Ivermectin for parasitic infections and it has been found to be extremely safe
New evidence shows that it has potent antiviral and anti-inflammatory properties as well
urge the Indian Government and all states in India to adopt Ivermectin as a matter of urgency as a front line prophylaxis and treatment for Covid-19
All India Institute of Medical Sciences and Indian Council of Medical Research have urgently responded with a recommendation to use Ivermectin in mild outpatient illness
We also recommend that Ivermectin be used as covid-19 prophylaxis
on a large scale through mass distribution of Ivermectin in the dose of 0.2mg/kg (12mg for a 60 kg person)
weekly to adults to decrease transmission amongst the general population in the current crisis
We believe this will save thousands of lives and reduces the suffering of millions.
Dr. Tess Lawrie, Dr Shashikanth Manikappa, Dr Pierre Kory
UPDATE As predicted, new and highly publicized RCTs “prove” IVM is ineffective. Interestingly, they were touted in the press before peer review or publication. These studies are wrought with conflicts of interest, funded by Gates Foundation and Oxford, the biggest profiteers of vaccines.
Full data is not available yet, but McMaster’s Mills’ study intially planned a single dose of Ivermectin, and appears to introduce it at 7-10 days after positive test, the exact opposite of the protocols used in all successful studies, hence, no effect.
While FLCCC is concerned that Delta’s viral load may call for increasing IVM dosage to twice per week, Tokyo’s Chief Medical Officer is calling for all out IVM campaign to stop their surge.
